---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006034"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:57:46.561432+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)

## Summary
- Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.
- Austedo US revs $435M (+28%); AJOVY global $137M (+21% local); Uzedy US $35M, FY outlook raised to ~$100M.
- Generics up 30% US, 8% Europe, 13% Int’l Markets (local currency); biosimilar to Prolia accepted by FDA/EMA.
- FY2024 guidance raised: rev $16.1-16.5B, Adj EBITDA $4.7-5.0B, Non-GAAP EPS $2.40-2.50.
- GAAP net loss $437M from $600M goodwill impairment and $450M legal provisions; cash from ops $693M.

## SEC filing metadata
- accession: 0001171843-24-006034
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184324006034/0001171843-24-006034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184324006034/f8k_110624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006034
- JSON: https://secwatch.observer/filing/0001171843-24-006034.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.